肺癌干细胞分离与鉴定研究进展_West China Medical Journal

Authors：

梅建东 , 蒲强 ,  刘伦旭

Corresponding author：

刘伦旭, Email: jiandongmei@yahoo.com.cn

Keywords：

肺癌; 肿瘤干细胞; 分离鉴定

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】 　随着肿瘤干细胞学说的兴起，肺癌干细胞研究也方兴未艾，肺癌干细胞可能在肺癌发生、进展过程中发挥关键作用。目前已发现肺癌发生可能与肺内成体干细胞有关，同时也有较多证据支持肺癌内存在肿瘤干细胞，但进一步研究肺癌干细胞的前提和基础是对其进行有效分离与鉴定，这是目前对肺癌干细胞进行深入研究所面临的主要障碍之一。CD133、ABCG2、ALDH等的表达可能与肺癌干细胞有关，现就文献中依靠上述标志物对肺癌干细胞进行分离及鉴定的方法与结果进行归纳探讨。

Citation： 梅建东,蒲强,刘伦旭. 肺癌干细胞分离与鉴定研究进展. West China Medical Journal, 2010, 25(11): 2114-2116. doi: Copy

1.	Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice[J]. Nature, 1994, 367(6464): 645-648.
2.	Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci USA, 2003, 100(7): 3983-3988.
3.	Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells[J]. Nature, 2004, 432(7015): 396-401.
4.	Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift[J]. Cancer Res, 2006, 66(4): 1883-1890.
5.	Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts[J]. Annu Rev Med, 2007, 58: 267-284.
6.	Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment[J]. Cell Bio, 2009, 106(38): 16281-16286.
7.	Eaves CJ. Cancer stem cells: here, there, everywhere?[J]. Nature, 2008, 456(7222): 581-582.
8.	Carney DN, Gazdar AF, Bunn PJ, et al. Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients[J]. Stem Cells, 1982, 1(3): 149-164.
9.	Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer[J]. Cell, 2005, 121(6): 823-835.
10.	Mori M, Rao SK, Popper HH, et al. Atypical adenomatous hyperplasia of the Lung: a probable forerunner in the development of adenocarcinoma of the lung[J]. Mod Pathol, 2001, 14(2): 72-84.
11.	Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population[J]. Cell Death Differ, 2008, 15(3): 504-514.
12.	Levina V, Marrangoni AM, DeMarco R, et al. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties[J]. PLoS One, 2008, 3(8): 3077.
13.	Tirino V, Camerlingo R, Franco R, et al. The role of CD133 in the identification and characterisation of tumor-initiating cells in non-small-cell lung cancer[J]. Eur J Cardiothorac Surg, 2009, 36(3): 446-453.
14.	Meng XJ, Li M, Wang XW, et al. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells[J]. Cancer Sci, 2009, 100(6): 1040-1046.
15.	Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo[J]. J Exp Med, 1996, 183 (4): 1797-1806.
16.	Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Brcp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side population phenotype[J]. Nat Med, 2001, 7(9): 1028-1034.
17.	Ho MM, Ng AV, Lam S, et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells[J]. Cancer Res, 2007, 67(10): 4827-4833.
18.	Sung JM, Cho HJ, Yi H, et al. Characterization of a stem cell population in lung cancer A549 cells[J]. Biochem Biophys Res Commun, 2008, 371(1): 163-167.
19.	Chen YC, Hsu HS, Chen YW, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells[J]. PLoS One, 2008, 3(7): 2637.
20.	Yoshida A, Rzhetsky A, Hsu LC, et al. Human aldehyde dehydrogenase gene family[J]. Eur J Biochem, 1998, 251(3): 549-557.
21.	Pearce DJ, Taussig D, Simpson C, et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples[J]. Stem Cells, 2005, 23(6): 752-760.
22.	Ginestier C, Hur MH, Jauffert EC, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome[J]. Cell Stem Cell, 2007, 1(5): 555-567.
23.	Ucar D, Cogle CR, Zucali JR, et al. Aldehyde dehydrogenase activity as a functional marker for lung cancer[J]. Chem Bio Interact, 2009, 178(1-3): 48-55.
24.	Jiang F, Qiu Q, Khanna A, et al. Aldehyde Dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer[J]. Mol Cancer Res, 2009, 7(3): 330-338.
25.	Zhou R, Liu Q, Todd NW, et al. Evaluation of aldehyde dehydrogenase 1 (ALDH1) as a marker of non-small cell lung cancer (NSCLC) stem cells (SCs) and correlation with prognosis[J]. J Clin Oncol, 2009, 27(Suppl 15): 11105.
26.	Mani SA, Guo WJ, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells[J]. Cell, 2008, 133(4): 704-715.
27.	Keshamouni VG, Michailidis G, Grasso CS, et al. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a mgratory/invasive phenotype[J]. J Proteome Res, 2006, 5(5): 1143-1154.
28.	Nozawa N, Hashimoto S, Nakashima Y, et al. Immunohistochemical alpha-and beta-caterfin and E-cadherin expression and their clinicopathologicaI significance in human lung adenocarcinoma[J]. Patho Res Pract, 2006, 202(9): 639-650.
29.	Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition[J]. Cancer Res, 2005, 65(20): 9455-9462.
30.	Gupta PB, Onder TT, Jiang GZ, et al, Identification of selective inhibitors of cancer stem cells by high-throughput screening[J]. Cell, 2009, 138(4): 645-659.

1. 　Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice[J]. Nature, 1994, 367(6464): 645-648.
2. 　Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci USA, 2003, 100(7): 3983-3988.
3. 　Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells[J]. Nature, 2004, 432(7015): 396-401.
4. 　Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift[J]. Cancer Res, 2006, 66(4): 1883-1890.
5. 　Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts[J]. Annu Rev Med, 2007, 58: 267-284.
6. 　Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment[J]. Cell Bio, 2009, 106(38): 16281-16286.
7. 　Eaves CJ. Cancer stem cells: here, there, everywhere?[J]. Nature, 2008, 456(7222): 581-582.
8. 　Carney DN, Gazdar AF, Bunn PJ, et al. Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients[J]. Stem Cells, 1982, 1(3): 149-164.
9. 　Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer[J]. Cell, 2005, 121(6): 823-835.
10. 　Mori M, Rao SK, Popper HH, et al. Atypical adenomatous hyperplasia of the Lung: a probable forerunner in the development of adenocarcinoma of the lung[J]. Mod Pathol, 2001, 14(2): 72-84.
11. 　Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population[J]. Cell Death Differ, 2008, 15(3): 504-514.
12. 　Levina V, Marrangoni AM, DeMarco R, et al. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties[J]. PLoS One, 2008, 3(8): 3077.
13. 　Tirino V, Camerlingo R, Franco R, et al. The role of CD133 in the identification and characterisation of tumor-initiating cells in non-small-cell lung cancer[J]. Eur J Cardiothorac Surg, 2009, 36(3): 446-453.
14. 　Meng XJ, Li M, Wang XW, et al. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells[J]. Cancer Sci, 2009, 100(6): 1040-1046.
15. 　Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo[J]. J Exp Med, 1996, 183 (4): 1797-1806.
16. 　Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Brcp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side population phenotype[J]. Nat Med, 2001, 7(9): 1028-1034.
17. 　Ho MM, Ng AV, Lam S, et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells[J]. Cancer Res, 2007, 67(10): 4827-4833.
18. 　Sung JM, Cho HJ, Yi H, et al. Characterization of a stem cell population in lung cancer A549 cells[J]. Biochem Biophys Res Commun, 2008, 371(1): 163-167.
19. 　Chen YC, Hsu HS, Chen YW, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells[J]. PLoS One, 2008, 3(7): 2637.
20. 　Yoshida A, Rzhetsky A, Hsu LC, et al. Human aldehyde dehydrogenase gene family[J]. Eur J Biochem, 1998, 251(3): 549-557.
21. 　Pearce DJ, Taussig D, Simpson C, et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples[J]. Stem Cells, 2005, 23(6): 752-760.
22. 　Ginestier C, Hur MH, Jauffert EC, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome[J]. Cell Stem Cell, 2007, 1(5): 555-567.
23. 　Ucar D, Cogle CR, Zucali JR, et al. Aldehyde dehydrogenase activity as a functional marker for lung cancer[J]. Chem Bio Interact, 2009, 178(1-3): 48-55.
24. 　Jiang F, Qiu Q, Khanna A, et al. Aldehyde Dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer[J]. Mol Cancer Res, 2009, 7(3): 330-338.
25. 　Zhou R, Liu Q, Todd NW, et al. Evaluation of aldehyde dehydrogenase 1 (ALDH1) as a marker of non-small cell lung cancer (NSCLC) stem cells (SCs) and correlation with prognosis[J]. J Clin Oncol, 2009, 27(Suppl 15): 11105.
26. 　Mani SA, Guo WJ, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells[J]. Cell, 2008, 133(4): 704-715.
27. 　Keshamouni VG, Michailidis G, Grasso CS, et al. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a mgratory/invasive phenotype[J]. J Proteome Res, 2006, 5(5): 1143-1154.
28. 　Nozawa N, Hashimoto S, Nakashima Y, et al. Immunohistochemical alpha-and beta-caterfin and E-cadherin expression and their clinicopathologicaI significance in human lung adenocarcinoma[J]. Patho Res Pract, 2006, 202(9): 639-650.
29. 　Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition[J]. Cancer Res, 2005, 65(20): 9455-9462.
30. 　Gupta PB, Onder TT, Jiang GZ, et al, Identification of selective inhibitors of cancer stem cells by high-throughput screening[J]. Cell, 2009, 138(4): 645-659.

West China Medical Journal

肺癌干细胞分离与鉴定研究进展

Abstract Full text Figures/Tables Video References Cited by

Format

Content